APPILI THERAPEUTICS

In The Global Race 
Against Infectious Diseases

Internal Innovation; Active In-Licensing.

Appili Therapeutics is proud to be at the forefront of global efforts to address serious infectious disease threats.

Our systematic approach to building a diverse pipeline provides investment opportunities that serve the needs of patients, payers, and clinicians. Our strategy centers on identifying unmet medical needs, rather than adhering to a specific platform or technology, and matching those needs with potential solutions in the marketplace. This approach provides financial stability and the opportunity to leverage a broad range of government and industry programs, as well as to develop transformative programs that can impact the fundamental treatment landscape for many types of infections.

Latest News

INVESTOR QUICK LINKS

VIDEO: Appili Therapeutics is well funded and working to combat infectious diseases

December 23, 2021
Appili Therapeutics – Press Release Correction
December 22, 2021
Appili Therapeutics Announces Update to Funding Agreement with The Lind Partners
November 19, 2021
Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Study Evaluating Biodefense Vaccine Candidate ATI-1701 and Change to Board of Directors
November 12, 2021
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2022 and Change of Chief Financial Officer